Physician profile
Mugurel Bazavan
NPI 1255562146
$1,196.97
in general payments reported to CMS, 2019-2025
10 companies · $82.10 in 2025
The $82.10 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $88.10 · 2022: $242 · 2023: $198 · 2024: $421 · 2025: $82.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $453.58 | 2022-2025 | Mitraclip, Cardiomems |
| Edwards Lifesciences Corporation | $174.43 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $125.37 | 2024 | Resonate El Icd Vr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.14 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $120.69 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $88.10 | 2021 | |
| Abiomed | $44.53 | 2019 | |
| Impulse Dynamics (USA) INC. | $31.46 | 2025 | Optimizer |
| Pfizer INC. | $30.61 | 2025 | |
| Cvrx, INC. | $7.06 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mugurel Bazavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.